Prestige Consumer Healthcare executives projected a $1.1 billion revenue and adjusted diluted EPS of $4.54 for fiscal 2026, weeks before Q4 results fell materially short -- Levi & Korsinsky investigates whether shareholders were adequately informed.

Shareholders who lost money on Prestige Consumer Healthcare (NYSE: PBH) stock following the Company's Q4 FY 2026 earnings miss are encouraged to submit their information to discuss their legal rights. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

During the Q3 FY 2026 earnings call, CEO Ron Lombardi highlighted that management had “narrowed our sales outlook,” revising revenue expectations to the floor of the prior range, “forecasting approximately $1.1 billion in revenue.” On the same call, management “expect[ed] sequential improvement in Clear Eyes supply again in Q4” resulting in projected EPS to “follow sales and narrow to an adjusted diluted EPS of approximately $4.54.” When the full-year results were disclosed on May 13, 2026, both metrics came up short.

Levi & Korsinsky is investigating whether Prestige Consumer Healthcare’s officers and directors made materially false or misleading statements regarding the Company's margin trajectory and cash flow outlook. Specifically, the investigation examines whether management possessed information at the time of the Q3 call that contradicted the projections communicated to shareholders.

PBH shareholders who suffered losses are encouraged to click here to discuss their legal options. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

Levi & Korsinsky, LLP | Top 50 Securities Firm | (212) 363-7500 | www.zlk.com

Frequently Asked Questions About the PBH Investigation

Q: Who is conducting the PBH investigation? A: Levi & Korsinsky, LLP is investigating potential securities fraud on behalf of investors who purchased PBH securities and suffered financial losses. The firm is nationally recognized, ranked in the ISS Top 50 for seven consecutive years, and has recovered hundreds of millions of dollars for aggrieved investors.

Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether Prestige Consumer Healthcare made materially false or misleading statements regarding its financial projections and growth expectations. Particularly as the stock price declined sharply when actual results fell shy of internal metrics.

Q: What do PBH investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at jlevi@levikorsinsky.com or (212) 363-7500. No immediate action is required to remain eligible to participate in the investigation.

Q: What if I already sold my PBH shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought PBH and sold at a loss may still participate in the investigation.

Q: What does it cost me to participate? A: Nothing. Securities investigations and any resulting actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.

Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260519507773/en/